Biovica
Dag Hammarskjölds väg 54B
Uppsala Science Park
Uppsala
752 37
Tel: 46-0-18-44-44-830
Fax: 46-0-18-57-24-28
Website: http://biovica.com/
Email: info@biovica.com
About Biovica
Biovica is a biotech company founded in 2009, focused on providing biomarkers and tools to better evaluate cancer therapies and predict treatment response. Biovica aim to contribute to personalized healthcare and better outcome for cancer patients by improved evaluation of therapy response and minimizing overtreatment.YEAR FOUNDED:
2009
LEADERSHIP:
CEO: Anders Rylander
79 articles about Biovica
-
DiviTum(R) TKa in Observational Trial
4/12/2024
Biovica International Biovica, active in cancer monitoring, announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida.
-
Nomination Committee for Biovica International AB for the 2024 Annual General Meeting
4/11/2024
Biovica International The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2023, and the Chairman of the Board.
-
Q3 Interim Report November-January 2023/2024
3/14/2024
Biovica International Several new commercial agreements signed and evidence that DiviTum® TKa significantly improves clinical routines in the USA.
-
Biovica Signs Master Service Agreement
3/12/2024
Biovica International Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a biopharmaceutical company enabling Biovica to provide its TKa testing assay and testing services.
-
Biovica Signs Master Service Agreement for TKa Testing with Leading Pharma Company
3/7/2024
Biovica International Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services.
-
DiviTum(R) TKa in Three Posters at the World's Largest Breast Cancer Symposium
12/5/2023
Biovica International Biovica, active in cancer monitoring, announces that three abstracts based on studies using the blood test DiviTum® TKa will be presented at the world's largest breast cancer symposium, SABCS, in early December.
-
Biovica Receives License for Maryland State
12/1/2023
Biovica International Biovica, active in cancer diagnostics, announces that the company has received a license for Maryland state, the 18th largest state in the US.
-
Q2 Interim Report August-October 2023/2024
11/28/2023
Biovica International Continued sales growth and several commercial agreements signed.
-
Biovica International's Invitation to Webcast for Q2 2023/2024
11/24/2023
Biovica International publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET.
-
Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare Effective 1st January 2024
11/21/2023
Biovica International Biovica, active in cancer monitoring, announces that the Center for Medicare & Medicaid Services after reviewing public comments, has agreed with the minority CDLT panel to crosswalk DiviTum TKa to reimbursement code 0058U.
-
Biovica Signs Commercial Partner for the DiviTum(R) TKa Assay in the Nordics
11/13/2023
Biovica International announces that the company has signed a commercial partnership agreement for the Nordics with Axlab A/S to commercialize the DiviTum® TKa assay.
-
Biovica receives CAP Accreditation for its CLIA Laboratory
10/16/2023
Biovica announces that it has received Laboratory Accreditation from the College of American Pathologists for its Clinical Laboratory Improvement Amendments -certified laboratory in San Diego, California.
-
Biovica Signs Agreement for DiviTum(R) TKa with World Re-known Cancer Clinic
10/12/2023
Biovica International Biovica, active in cancer monitoring, announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida.
-
DiviTum(R) TKa to pursue Gap-fill process for CMS pricing decision
9/28/2023
Biovica International Biovica, active in cancer monitoring, announces that the Center for Medicare & Medicaid Services has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024.
-
Biovica signs US agreement with leading healthcare provider in Arizona
9/19/2023
Biovica announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona.
-
Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial
8/24/2023
Biovica International, active in cancer diagnostics, announces the initiation of a prospective clinical trial to study the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients.
-
Notice of Annual General Meeting in Biovica International AB - August 4, 2023
8/4/2023
Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, are hereby invited to the annual general meeting to be held on Tuesday 5 September 2023, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjolds Vag 38 in Uppsala.
-
Biovica Signs US Commercial Agreement with Occum Health
7/31/2023
Biovica announces that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners.
-
Biovica achieves PLA code for Medicare
7/21/2023
Biovica International Biovica, active in cancer monitoring, announces that the company has received a PLA code from the AMA, an important milestone in the commercialization of DiviTum® TKa in the United States.
-
Biovica International AB - Annual Report for the Financial Year 2022/2023 Published
6/30/2023
Biovica International Annual report for the financial year 2022/2023 for Biovica International AB is published on our website.